A rare inherited neuromuscular disorder (genetically confirmed)
TSR-405 against placebo in an inherited neuromuscular disorder. Sponsor: Tailspin Rare Diseases (fictional), Rare disease.
Five leading KPIs warn whether recruitment will reach its target, with the screening funnel and the corrective actions that have evidence behind them.
KPIs at a glance
Data to September 30th 2026. Each measure links to its chart below.
Will the plan work?
18 of 18 planned
On course The plan spreads each country's sites over its start-up window
Is recruitment on course?
Will the plan work?
The plan needs 18 sites, 6.2% of what its countries can supply, against none competing trials. That leaves room to add sites if recruitment falls behind.
Sites are opening on schedule
Sites openNumber, by month, against the plan spread over each country's start-up window
Show data
| Month | Planned | Actual |
|---|---|---|
| Sep 2024 | 0 | 0 |
| Dec 2024 | 0 | 0 |
| Mar 2025 | 0 | 0 |
| Jun 2025 | 6 | 5 |
| Sep 2025 | 13 | 14 |
| Dec 2025 | 16 | 18 |
| Mar 2026 | 18 | 18 |
| Jun 2026 | 18 | 18 |
| Sep 2026 | 18 | 18 |
| Oct 2026 | 18 | 18 |
Sources: epiClinical synthetic sites; start-up windows from the planner parameters (D25)
Each site found its first patient in the expected time
Open sites by countryMonths from activation to first patient; hollow dots have none yet; orange marks a wait longer than nine in ten similar sites, or none randomised despite three or more expected
Show data
| Site | Country | Months to first patient | Flagged |
|---|---|---|---|
| 405-US-01, Seattle | United States | None yet, 15.1 months open | No |
| 405-US-02, Chicago | United States | None yet, 17.6 months open | No |
| 405-US-03, Phoenix | United States | None yet, 17.0 months open | No |
| 405-US-04, Los Angeles | United States | None yet, 13.2 months open | No |
| 405-US-05, Nashville | United States | None yet, 14.0 months open | No |
| 405-US-06, Denver | United States | 5.4 | No |
| 405-UK-01, Sheffield | United Kingdom | None yet, 13.9 months open | No |
| 405-UK-02, Cardiff | United Kingdom | None yet, 14.1 months open | No |
| 405-UK-03, Liverpool | United Kingdom | None yet, 16.2 months open | No |
| 405-UK-04, Edinburgh | United Kingdom | None yet, 13.6 months open | No |
| 405-ES-01, Seville | Spain | 1.2 | No |
| 405-ES-02, Alicante | Spain | None yet, 13.6 months open | No |
| 405-ES-03, Oviedo | Spain | None yet, 13.9 months open | No |
| 405-PL-01, Olsztyn | Poland | None yet, 11.2 months open | No |
| 405-PL-02, Kraków | Poland | None yet, 12.0 months open | No |
| 405-TR-01, Istanbul | Turkey | None yet, 14.7 months open | No |
| 405-IN-01, Lucknow | India | 0.6 | No |
| 405-IN-02, Chennai | India | 12.9 | No |
Source: epiClinical synthetic sites. A slow site can wait months for its first patient by design, so each is judged against its own expected rate. At study level, a first patient more than about 70 days after the first site opened predicted slow accrual (MD Anderson, 4,269 trials). That alert, 2.3 months, drives the scorecard. It is a cut-off from historical data, not a standard.
Is recruitment on course?
Recruitment is behind the plan
Patients randomisedCumulative, against the count the plan expects from each country's rate and opening window
Show data
| Month | Planned | Actual |
|---|---|---|
| Sep 2024 | 0 | 0 |
| Dec 2024 | 0 | 0 |
| Mar 2025 | 0 | 0 |
| Jun 2025 | 0 | 0 |
| Sep 2025 | 2 | 1 |
| Dec 2025 | 4 | 3 |
| Mar 2026 | 7 | 4 |
| Jun 2026 | 11 | 5 |
| Sep 2026 | 14 | 7 |
| Oct 2026 | 15 | 7 |
Sources: epiClinical synthetic sites; plan from the planner. Studies under 60% of target at the planned end rarely recovered in NCI data (review note 02).
Which sites are behind their expectation?
Patients randomised as a share of those expectedEach dot a site, against the patients it was expected to recruit since it opened
Show data
| Site | Country | Expected | Randomised | Observed ÷ expected | Judgement |
|---|---|---|---|---|---|
| 405-US-01, Seattle | United States | 0.6 | 0 | ×0 | Within normal variation |
| 405-US-02, Chicago | United States | 0.7 | 0 | ×0 | Within normal variation |
| 405-US-03, Phoenix | United States | 0.6 | 0 | ×0 | Within normal variation |
| 405-US-04, Los Angeles | United States | 0.7 | 0 | ×0 | Within normal variation |
| 405-US-05, Nashville | United States | 0.5 | 0 | ×0 | Within normal variation |
| 405-US-06, Denver | United States | 1.6 | 2 | ×1.216 | Within normal variation |
| 405-UK-01, Sheffield | United Kingdom | 1.1 | 0 | ×0 | Within normal variation |
| 405-UK-02, Cardiff | United Kingdom | 1.1 | 0 | ×0 | Within normal variation |
| 405-UK-03, Liverpool | United Kingdom | 0.9 | 0 | ×0 | Within normal variation |
| 405-UK-04, Edinburgh | United Kingdom | 1.1 | 0 | ×0 | Within normal variation |
| 405-ES-01, Seville | Spain | 0.8 | 2 | ×2.386 | Within normal variation |
| 405-ES-02, Alicante | Spain | 0.7 | 0 | ×0 | Within normal variation |
| 405-ES-03, Oviedo | Spain | 1.1 | 0 | ×0 | Within normal variation |
| 405-PL-01, Olsztyn | Poland | 0.8 | 0 | ×0 | Within normal variation |
| 405-PL-02, Kraków | Poland | 1.0 | 0 | ×0 | Within normal variation |
| 405-TR-01, Istanbul | Turkey | 0.5 | 0 | ×0 | Within normal variation |
| 405-IN-01, Lucknow | India | 0.7 | 2 | ×3.061 | Within normal variation |
| 405-IN-02, Chennai | India | 0.7 | 1 | ×1.487 | Within normal variation |
Source: epiClinical synthetic sites. Allowing for site spread (coefficient of variation 0.9), a site expected to recruit a handful of patients can recruit none and still be within normal variation. Poisson-only limits flag far more sites.
Pooled, no country or region is outside its range; the United Kingdom is furthest behind at ×0.00
Sites grouped by country and flagged regionPatients randomised as a share of those expected; the bar is where an ordinary group of that size would land
Show data
| Group | Sites | Randomised | Expected | Observed ÷ expected | Ordinary range | Judgement |
|---|---|---|---|---|---|---|
| United States | 6 | 2 | 4.7 | ×0.429 | ×0.059 to ×2.451 | Within normal variation |
| United Kingdom | 4 | 0 | 4.2 | ×0 | ×0.004 to ×2.585 | Within normal variation |
| Spain | 3 | 2 | 2.6 | ×0.764 | ×0 to ×3.001 | Within normal variation |
| Poland | 2 | 0 | 1.8 | ×0 | ×0 to ×3.49 | Within normal variation |
| Turkey | 1 | 0 | 0.5 | ×0 | ×0 to ×5.763 | Within normal variation |
| India | 2 | 3 | 1.3 | ×2.263 | ×0 to ×3.784 | Within normal variation |
Source: epiClinical synthetic sites
Where patients are lost before randomisation
Benchmarks for each step from referral to randomisation. Screen failure explains where patients are lost; on its own it does not predict whether a study reaches its target.
| Step | Typical conversion | Source |
|---|---|---|
| Trial available at the patient's centre (cancer care) | 44.4% (100% minus 55.6% with no trial available) | Unger 2019, JNCI, https://doi.org/10.1093/jnci/djy221 |
| Eligible, among patients with a trial available (cancer care, derived) | about 52% ((14.8 + 8.1) / 44.4). Note: the often-quoted 78.5% appears to be 100% minus 21.5%, a misreading because 21.5% is a share of all patients | Unger 2019, JNCI, https://doi.org/10.1093/jnci/djy221 |
| Eligible among screened (primary care trials) | median 83% (IQR 40% to 100%) | Jones 2009, BMC Family Practice, https://doi.org/10.1186/1471-2296-10-5 |
| Eligible among screened (knee osteoarthritis trials) | median 71.9% | Koog et al., Archives of Rheumatology, https://archivesofrheumatology.org/full-text/650 |
| Approached among eligible (one oncology trial) | 91% | Lewis 2020, Trials, https://doi.org/10.1186/s13063-020-04559-w |
| Agreed among those offered a trial (cancer trials, 35 studies) | about 55% (55.0% treatment, 55.3% cancer control) | Unger 2021, JNCI, https://doi.org/10.1093/jnci/djaa155 |
| Agreed among approached (one oncology trial) | 40% | Lewis 2020, Trials, https://doi.org/10.1186/s13063-020-04559-w |
| Consented and randomised among eligible (388 NIHR trials) | median 72% (IQR 50% to 88%) | Jacques 2022, BMJ Open, https://doi.org/10.1136/bmjopen-2021-059230 |
| Enrolled among eligible (primary care trials) | median 74% (IQR 49% to 92%) | Jones 2009, BMC Family Practice, https://doi.org/10.1186/1471-2296-10-5 |
| Enrolled among all cancer patients (end to end) | 8.1% (15.9% academic, 7% community centres) | Unger 2019, JNCI, https://doi.org/10.1093/jnci/djy221 |
| Screen failure after consent (oncology, one LMIC centre, 15 RCTs) | 51% failed (49% randomised); main causes inclusion criteria not met 54.9%, declined treatment 22.2% | Parekh 2022, ecancermedicalscience, https://doi.org/10.3332/ecancer.2022.1476 |
| Screen failure after consent (prodromal Alzheimer's, industry source) | 76% to 80% in two trials, against a typical 25% to 30% (grade D, not peer-reviewed) | Worldwide Clinical Trials 2017 blog, https://www.worldwide.com/blog/2017/10/unique-4-step-approach-limits-high-screen-failure-in-alzheimers-disease-research-part-1/ |
| Retained with valid primary outcome among randomised (388 NIHR trials) | median 88% (IQR 80% to 97%) | Jacques 2022, BMJ Open, https://doi.org/10.1136/bmjopen-2021-059230 |
| Recruitment rate (388 NIHR trials) | median 0.95 participants per centre per month (IQR 0.42 to 2.60) | Jacques 2022, BMJ Open, https://doi.org/10.1136/bmjopen-2021-059230 |
| Consent to randomisation interval | no published benchmark found; protocol-specific, label any default Illustrative | none found |
What works when a measure goes red
The evidence review's 16 corrective and preventive actions (CAPAs), strongest evidence first. Grade A is strong, D means no quantitative evidence was found.
| Action | Grade | Answers | Effect |
|---|---|---|---|
| Telephone follow-up of people who did not reply to an invitation | A | low enrolment rate; low response to invitation letters | Risk difference +6 percentage points (95% CI 3 to 9), high certainty, clearest where baseline recruitment is low (under about 10% of those invited). Earlier version: RR 1.66 (95% CI 1.03 to 2.46), 2 studies, 1,058 participants. |
| Open rather than blinded placebo design (design stage only) | A | predicted low enrolment at feasibility; high refusal linked to placebo | Risk difference +10 percentage points (95% CI 7 to 13), high certainty. |
| Monetary thank-you for returning follow-up questionnaires | B | high drop-out; missing primary outcome data; low questionnaire return | Postal: RR 1.18 (95% CI 1.09 to 1.28); higher vs lower value RR 1.12 (1.04 to 1.22); electronic, offered on receipt, RR 1.25 (1.14 to 1.38). 2021 update: incentive vs usual follow-up RR 1.20 (1.06 to 1.36), 3 studies, 3,166 participants, low certainty. |
| Pre-notification before follow-up, with reward or reminder | B | high drop-out; low questionnaire return | Monetary reward with reminder or pre-notification improved retention, moderate certainty; no pooled number extracted. PROMETHEUS SWATs found pre-notification effective; no effect size in the abstract. |
| Reduce follow-up burden (home self-sampling, no extra diaries) | B | high drop-out; missed visits; missing primary outcome data | Self-sampling kits improved retention, moderate certainty (no pooled number extracted). Adding a diary reduced retention: RR 0.97 (95% CI 0.96 to 0.98), 2 studies, 9,906 participants, moderate certainty. |
| Opt-out contact for potential participants | C | low enrolment rate; few patients approached | RR 1.39 (95% CI 1.06 to 1.84), but from a single study of 152 people; not among the high-certainty findings of the 2018 update. |
| Personalised text messages for follow-up | C | high drop-out; low questionnaire return | Mixed: PROMETHEUS found personalised texts improved questionnaire response (no effect size in abstract); Cochrane pooled electronic reminders RR 1.01 (95% CI 0.95 to 1.09), 3 studies, 790 participants, low certainty. |
| Broaden eligibility criteria by protocol amendment | C | high screen failure; low eligible-to-screened ratio; low enrolment rate | Modelled in advanced NSCLC real-world data (61,094 patients): relaxing restrictive criteria more than doubled the eligible pool on average, with hazard ratio change of about 0.05 and no rise in toxicity-related discontinuation. No prospective evidence of the effect on actual randomisations. Amendments: median direct cost about $141k (phase II) and $535k (phase III), about 3 months added. |
| Participant payments or reimbursement | C | low consent among approached; low enrolment rate | Mixed in two RCTs: smoking-cessation trial consent 21.8% ($0) vs 35.9% ($200) vs 47.1% ($500); ambulation trial no effect (45.4%, 48.1%, 43.0%). No evidence of undue inducement in these low-risk trials. |
| Add decentralised elements | C | low enrolment rate; high drop-out; patients living far from sites | Of 13 studies, 10 or 11 reported better recruitment with decentralised methods, mostly without head-to-head comparison; a 2022 systematic review found insufficient comparable data to say whether decentralised trials recruit or retain better. |
| Screening-log review to find the leaking funnel stage | C | any red recruitment KPI; high screen failure; low consent among approached | No quantitative evidence that logs raise recruitment. In one oncology trial, logs showed 91% of eligible patients approached but 40% agreeing, pointing at the consent conversation; logs were incomplete (47% returned; 28% of enrolled patients missing). |
| Close or replace non-enrolling sites | D | sites with zero enrolment; low site productivity; slow activation | No quantitative evidence on the effect of closing sites. Context only: 11% of activated sites enrol no one and 37% under-enrol (Tufts CSDD 2012 data). |
| Add sites or countries | D | low enrolment rate; forecast misses last patient in date | No quantitative evidence on adding sites as a rescue. Diminishing returns follow from activation lag and site variability rather than from a measured effect. Context: median 0.95 participants per centre per month (IQR 0.42 to 2.60) in NIHR trials. |
| Increase site or investigator payments | D | low site productivity; low enrolment rate | No quantitative evidence for patient recruitment; a 2005 systematic review found almost no experimental evidence and raised conflict-of-interest concerns. One RCT of paying doctors concerned recruiting doctors as study subjects, not patient recruitment. |
| Central campaigns, recruitment vendors and referral networks | D | few patients identified; no trial available at local centres; low enrolment rate | No quantitative evidence found in peer-reviewed comparative studies within this review. Context: in cancer care, no trial was available at the patient's centre for 55.6% of patients, which referral networks aim to address. |
| Site re-training and extra site support visits | D | low site productivity; low approach rate; high screen failure from avoidable errors | No quantitative evidence found; the 2021 Cochrane retention review found only two studies targeting site staff. |